Pipeline

                          Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

                          Pipeline

                          HIV / AIDS

                          Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

                          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                          • Emtricitabine and tenofovir alafenamide

                            Potential Indication: PrEP

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-9131 (NRTI)

                            Potential Indication: HIV/AIDS

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-6207 (Capsid Inhibitor)

                            Potential Indication: HIV/AIDS

                            Phase 1
                            Phase 2
                            Phase 3
                          • Vesatolimod (TLR-7 agonist)

                            Potential Indication: HIV/AIDS

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-9722 (bNab)

                            Potential Indication: HIV/AIDS

                            Phase 1
                            Phase 2
                            Phase 3

                          Liver Diseases

                          Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

                          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                          • Selonsertib (ASK-1 inhibitor)

                            Potential Indication: DKD

                            Phase 1
                            Phase 2
                            Phase 3
                          • Cilofexor (FXR agonist)

                            Potential Indication: NASH

                            Phase 1
                            Phase 2
                            Phase 3
                          • Cilofexor (FXR agonist)

                            Potential Indication: Primary Biliary Cirrhosis

                            Phase 1
                            Phase 2
                            Phase 3
                          • Cilofexor (FXR agonist)

                            Potential Indication: Primary Sclerosing Cholangitis

                            Phase 1
                            Phase 2
                            Phase 3
                          • Firsocostat (ACC Inhibitor)

                            Potential Indication: NASH

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-9688 (TLR-8 agonist)

                            Potential Indication: HBV

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-4224 (PD-L1)

                            Potential Indication: HBV

                            Phase 1
                            Phase 2
                            Phase 3

                          Hematology / Oncology

                          Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

                          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                          • Axicabtagene ciloleucel

                            Trial: ZUMA-5 Potential Indication: Indolent NHL

                            Phase 1
                            Phase 2
                            Phase 3
                          • Axicabtagene ciloleucel

                            Trial: ZUMA-6 Potential Indication: DLBCL (PD-L1 mAb)

                            Phase 1
                            Phase 2
                            Phase 3
                          • Axicabtagene ciloleucel

                            Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

                            Phase 1
                            Phase 2
                            Phase 3
                          • Axicabtagene ciloeucel

                            Trial: ZUMA-11 Potential Indication: DLBCL (41BB)

                            Phase 1
                            Phase 2
                            Phase 3
                          • Axicabtagene ciloeucel

                            Trial: ZUMA-12 Potential Indication: 1st line DLBCL

                            Phase 1
                            Phase 2
                            Phase 3
                          • KTE-X19

                            Trial: ZUMA-2 Potential Indication: MCL

                            Phase 1
                            Phase 2
                            Phase 3
                          • KTE-X19

                            Trial: ZUMA-3 Potential Indication: Adult ALL

                            Phase 1
                            Phase 2
                            Phase 3
                          • KTE-X19

                            Trial: ZUMA-4 Potential Indication: Pediatric ALL

                            Phase 1
                            Phase 2
                            Phase 3
                          • KTE-X19

                            Trial: ZUMA-8 Potential Indication: CLL

                            Phase 1
                            Phase 2
                            Phase 3
                          • KITE-718 (MAGE A3/A6)

                            Potential Indication: Solid Tumor

                            Phase 1
                            Phase 2
                            Phase 3
                          • KITE-439 (HPV E7)

                            Potential Indication: Solid Tumor

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-1423 (Bi-specific antibody)

                            Potential Indication: Solid Tumor

                            Phase 1
                            Phase 2
                            Phase 3

                          Inflammation / Respiratory

                          Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

                          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                          • Filgotinib (JAK1 inhibitor)

                            Potential Indication: Rheumatoid Arthritis

                            Phase 1
                            Phase 2
                            Phase 3
                          • Filgotinib (JAK1 inhibitor)

                            Potential Indication: Crohn's Disease

                            Phase 1
                            Phase 2
                            Phase 3
                          • Filgotinib (JAK1 inhibitor)

                            Potential Indication: Ulcerative Colitis

                            Phase 1
                            Phase 2
                            Phase 3
                          • Filgotinib (JAK1 inhibitor)

                            Potential Indication: Inflammatory Diseases

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-9876 (Syk inhibitor)

                            Potential Indication: Sjogren’s Syndrome

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-9876 (Syk inhibitor)

                            Potential Indication: Lupus

                            Phase 1
                            Phase 2
                            Phase 3
                          • GS-4875 (TPL2 inhibitor)

                            Potential Indication: Inflammatory Bowel Disease

                            Phase 1
                            Phase 2
                            Phase 3

                          Other

                          Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

                          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                          • Remdesivir (GS-5734, Nuc inhibitor)

                            Potential Indication: Ebola Virus Infection

                            Phase 1
                            Phase 2
                            Phase 3

                          Some of the content on this page is not intended for users outside the US.

                          九九99香蕉在线视频